NASDAQ$IMUX
Immunic Inc · Q1 2025 earnings
Q1 2025 earnings · · Investor relations
Briefing
Immunic reported Q1 2025, a net loss of $12.4M, diluted EPS of ($0.18).
For Q1 2025, Immunic reported a net loss of $12.4M, diluted EPS was ($0.18). The filing highlights segment performance, liquidity, and management commentary on the period.
- Net loss $12.4M.
- Diluted EPS ($0.18).
- Immunic discusses capital allocation and near-term priorities in MD&A.
Headline financials
Revenue & EPS history
Immunic · Revenue · Quarterly
$0
Forward guidance
Life-sciences filers emphasize pipeline milestones, regulatory paths, and cash runway; product revenue may be limited or emerging.
Tailwinds
- Pipeline progress and partnership optionality.
- Cash balances funding operations into catalysts.
- Commercial launches where approved.
Headwinds
- Trial failure or regulatory delay risk.
- Reimbursement and competitive pressure.
- Dilution from equity raises.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2025
+0.1%
Avg return
Earnings day
-0.1%
Avg return
5 days after
-4.5%
Avg return
30 days after
37%
17 / 46 earnings
Positive
+37.0%
Q2 2022
Best reaction
-16.4%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -3.8% | -1.7% | +15.5% | |
| Q3 2025 | -6.3% | +0.0% | -18.2% | |
| Q4 2024 | -2.1% | -28.1% | -22.7% | |
| Q1 2025 | -4.8% | -7.8% | -26.4% | |
| Q3 2024 | +0.0% | -2.5% | +8.5% | |
| Q1 2024 | -10.1% | -9.1% | -10.9% | |
| Q4 2023 | -4.7% | +8.6% | +3.1% | |
| Q3 2023 | +3.2% | +9.4% | +50.7% | |
| Q2 2023 | -6.9% | -8.8% | -20.4% | |
| Q1 2023 | -2.8% | -5.0% | -3.9% | |
| Q4 2022 | +0.0% | +4.8% | -21.7% | |
| Q3 2022 | -11.1% | -12.3% | -20.5% | |
| Q2 2022 | +37.0% | +29.0% | +16.7% | |
| Q1 2022 | +0.4% | +12.1% | -25.1% | |
| Q4 2021 | -9.4% | -3.2% | -0.4% | |
| Q3 2021 | +2.1% | +1.1% | -16.7% | |
| Q2 2021 | +21.7% | +17.1% | +25.5% | |
| Q1 2021 | -8.3% | -8.1% | -2.8% | |
| Q4 2020 | +0.5% | -1.7% | -5.7% | |
| Q3 2020 | +4.4% | +7.3% | +10.7% | |
| Q2 2020 | +27.9% | +8.7% | -11.6% | |
| Q1 2020 | +18.3% | +20.3% | +53.9% | |
| Q4 2019 | -16.4% | -19.3% | +19.3% | |
| Q3 2019 | -6.4% | -6.2% | -17.3% | |
| Q2 2019 | +0.4% | +4.6% | +6.4% | |
| Q1 2019 | +7.1% | -16.1% | -58.8% | |
| Q4 2018 | -11.1% | -8.3% | -17.8% | |
| Q3 2018 | -7.0% | -9.9% | -18.9% | |
| Q2 2018 | -2.8% | +6.8% | -17.0% | |
| Q1 2018 | +0.9% | +2.7% | -11.7% | |
| Q4 2017 | -6.5% | +2.6% | +0.0% | |
| Q3 2017 | -4.5% | +4.5% | -7.3% | |
| Q2 2017 | +17.3% | +11.5% | +17.3% | |
| Q1 2017 | -4.0% | -17.3% | -17.3% | |
| Q4 2016 | -1.2% | +1.2% | -11.6% | |
| Q3 2016 | -1.0% | +8.6% | -4.8% | |
| Q2 2016 | +1.3% | -0.5% | -5.8% | |
| Q1 2016 | +3.9% | — | — | |
| Q4 2015 | -4.9% | — | — | |
| Q3 2015 | -3.9% | — | — | |
| Q2 2015 | +15.8% | — | — | |
| Q1 2015 | -5.6% | — | — | |
| Q4 2014 | -9.0% | — | — | |
| Q3 2014 | +5.0% | — | — | |
| Q2 2014 | -7.2% | — | — | |
| Q1 2014 | -0.1% | — | — | |
| Q2 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro